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Clinics 
Age and sex 
63 years old female patient. 
Previous history 
No preleukemia.  
Previous malignancy: patient diagnosed with rectal 
cancer 8/03 treated with surgery and adjuvant chemo 
and radiation therapy. 9/2008 stage II isolated 
metastatic colorectal cancer involving the lung. 
Patient was treated with surgical resection and 5FU 
therapy and radiation. Patient is currently in 
remission. Has sibling with renal cell carcinoma. 
No inborn condition of note  
Organomegaly 
No hepatomegaly, no splenomegaly, no enlarged 
lymph nodes, no central nervous system involvement.  
Blood 
WBC: 7.8X 109/l 
HB: 11.2g/dl 
Platelets: 176X 109/l 
Blasts: 18% (18-29% bone marrow/ 4% peripheral 
blood). 
Bone marrow : 28.3% segmented neutrophils, 10% 
eosinophils, 48.5% lymphocytes, 12.1% monocytes, 





Trilineage dyspoiesis consistent with myelodysplasia. 
Immunophenotype 
CD7: 44.4%, CD13: 67.5%, CD34: 28.7%, CD117: 
30.9%, HLA-DR: 38.5%, CD38: 71.4%. 
Rearranged Ig Tcr 
n/a 
Pathology 
Flow cytometric analysis of the specimen labeled 
bone marrow reveals a significant population of 
myeloblasts (approximately 29% of cells that could 
be studied in the sample) with most expressing 
abnormal CD7 (up to 1/3 is CD7 negative), CD13, 
CD33 (expression ranges from essentially 
undetectable up to moderately positive), CD34, 
CD38, CD45, CD117, and HLA-DR. Approximately 
half of the blast population is above the negativity 
threshold and shows dim to moderate intensity, 
CD123 expression. The remaining myeloid cells 
show minor abnormalities in antigen expression with 
respect to acquisition of full intensity CD13 and 
CD16. The change is less than typically occurs in 
well-defined MDS cases. 
Electron microscopy 
n/a 
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Fig. 1: Rare t(4;12)(q11;p13) found in a female patient with known history of metastatic colorectal cancer presenting with secondary 
high grade myelodysplastic syndrome. 
 
Fig. 2: Confirmation of 4q12 rearrangement using Vysis LSI 4q12 Tricolor Rearrangement Probe (Abbott). 
 
Diagnosis 
Flow cytometry- Acute myelogenous leukemia with 
~29% myeloblasts. Morphology- therapy-related 
myelodysplasia with 18% blasts. 
Survival 
Date of diagnosis: 07-2010 
Treatment: Patient is being treated with Vidasia, 
induction chemotherapy and salvage chemotherapy. 
Complete remission: Refractory AML s/p 
chemotherapy. 
Treatment related death: n/a 
Relapse: n/a 
Status: Alive 
Last follow up: 03-2012 
Survival: 20 months 
Karyotype 
Sample: Bone marrow 
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Karyotype at Relapse 
n/a 
Other molecular cytogenetics technics 
Interphase FISH using Vysis LSI 4q12 Tricolor 
Rearrangement Probe (Abbott). Interphase FISH 
using LSI break apart probe for ETV6 (Abbott) was 
attempted on destained slides, no signals were 
detected. 
Other molecular cytogenetics results 
nuc ish(SCFD2,LNX,PDGFRA,KIT)x2 (SCDF2 con 
LNX sep PDGFRA,KITx1). 
Other Molecular Studies 
Technics: 
OncoChip™ / CNE. Microarray analysis using a 
whole genome oligonucleotide array, which 
specifically targets genes, micro RNAs and specific 
genomic intervals with known or suspected relevance 
to cancer. 
Results: 
CNE Results. arr(1-22,X)x2 Normal Female. 
Unclear findings. arr 7q34(141,693,456-
141,719,136)x4,14q32.33(105,949,400-
105,987,288)x0~1. Finding TCR and IGH 
rearrangements in the same clone is not unheard of as
there is crosstalk. CNE hasn't been validated as a te t 
for clonality. 
Comments 
Rare t(4;12)(q12;p13) found in a 63 year old female 
with history of stage II isolated metastatic colorectal 
cancer involving the lung. Results were confirmed by 
interphase FISH utilizing Vysis 4q12 Tricolor 
Rearrangement Probe (Abbott). Microarray studies 
were conducted using OncoChip™ whole genome 
oligonucleotide array, and yielded the following 
results: CNE result arr(1-22,X)x2 Normal Female, 
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